AU2250097A - Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist - Google Patents
Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonistInfo
- Publication number
- AU2250097A AU2250097A AU22500/97A AU2250097A AU2250097A AU 2250097 A AU2250097 A AU 2250097A AU 22500/97 A AU22500/97 A AU 22500/97A AU 2250097 A AU2250097 A AU 2250097A AU 2250097 A AU2250097 A AU 2250097A
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- cyclooxygenase
- inhibitor
- arylamino
- leukotriene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 title abstract 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title abstract 3
- 239000003913 leukotriene B4 receptor antagonist Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- -1 cyano, carboxyl Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 abstract 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 abstract 1
- 125000004689 alkyl amino carbonyl alkyl group Chemical group 0.000 abstract 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000004470 heterocyclooxy group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60058096A | 1996-02-13 | 1996-02-13 | |
| US600580 | 1996-02-13 | ||
| PCT/US1997/001422 WO1997029775A1 (en) | 1996-02-13 | 1997-02-11 | Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2250097A true AU2250097A (en) | 1997-09-02 |
Family
ID=24404169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU22500/97A Abandoned AU2250097A (en) | 1996-02-13 | 1997-02-11 | Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US6172096B1 (enExample) |
| EP (2) | EP1640003A2 (enExample) |
| JP (1) | JP2000505445A (enExample) |
| AT (1) | ATE296114T1 (enExample) |
| AU (1) | AU2250097A (enExample) |
| CA (1) | CA2246356A1 (enExample) |
| DE (1) | DE69733338T2 (enExample) |
| ES (1) | ES2243978T3 (enExample) |
| PT (1) | PT880362E (enExample) |
| WO (1) | WO1997029775A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2223154A1 (en) | 1995-06-02 | 1996-12-05 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| US6512121B2 (en) | 1998-09-14 | 2003-01-28 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| AU1952597A (en) * | 1996-02-13 | 1997-09-02 | G.D. Searle & Co. | Combinations, having immunosuppressive effects, containing cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor |
| WO1997029776A1 (en) | 1996-02-13 | 1997-08-21 | G.D. Searle & Co. | Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors |
| ES2243978T3 (es) * | 1996-02-13 | 2005-12-01 | G.D. SEARLE & CO. | Composiciones que comprenden un inhibidor de la ciclooxigenasa-2 y un antagonista del receptor de leucotrieno b4. |
| US7041694B1 (en) * | 1997-12-17 | 2006-05-09 | Cornell Research Foundation, Inc. | Cyclooxygenase-2 inhibition |
| CA2313049A1 (en) * | 1997-12-17 | 1999-06-24 | Cornell Research Foundation, Inc. | Cyclooxygenase-2 inhibition |
| US6767890B1 (en) * | 1998-11-18 | 2004-07-27 | Coastside Bio Resources | Peptides having anti-cancer and anti-inflammatory activity |
| CA2408818A1 (en) * | 2000-05-11 | 2001-11-15 | Oklahoma Medical Research Foundation | Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity with ns398 or pdtc |
| GB0112348D0 (en) * | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
| EP1539240A2 (en) * | 2002-05-02 | 2005-06-15 | The Washington University | Methods and compositions for treating t cell mediated inflammatory/autoimmune diseases and disorders in subjects having a glucocorticoid regulation deficiency |
| US7507531B2 (en) | 2002-10-17 | 2009-03-24 | Decode Genetics Chf. | Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction |
| US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| US7354574B2 (en) * | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| RS20050390A (sr) * | 2002-11-26 | 2008-04-04 | Boehringer Ingelheim Pharma Gmbh. & Co.Kg., | Farmaceutska kompozicija koja obuhvata ltb4 antagonist i koks-2 inhibitor ili kombinovani koks1/2 inhibitor |
| US20040242676A1 (en) * | 2003-05-30 | 2004-12-02 | Alessi Thomas R. | Method of mitigating the adverse effects of IL-2 |
| US7083802B2 (en) * | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| JP2007505932A (ja) | 2003-09-18 | 2007-03-15 | マクサイト， インコーポレイテッド | 経強膜送達 |
| US7087237B2 (en) * | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
| US20050181018A1 (en) * | 2003-09-19 | 2005-08-18 | Peyman Gholam A. | Ocular drug delivery |
| US7083803B2 (en) * | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
| JP4793692B2 (ja) * | 2004-04-26 | 2011-10-12 | 小野薬品工業株式会社 | 新規なｂｌｔ２介在性疾患、ｂｌｔ２結合剤および化合物 |
| CN101014332A (zh) * | 2004-09-13 | 2007-08-08 | 参天制药株式会社 | 角膜结膜病变治疗剂 |
| CA2597590A1 (en) | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Formulations for ocular treatment |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| EP1879881A2 (en) * | 2005-04-14 | 2008-01-23 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
| US20070014760A1 (en) * | 2005-07-18 | 2007-01-18 | Peyman Gholam A | Enhanced recovery following ocular surgery |
| WO2007011880A2 (en) | 2005-07-18 | 2007-01-25 | Minu, L.L.C. | Enhanced ocular neuroprotection/neurostimulation |
| KR101478164B1 (ko) | 2006-02-09 | 2014-12-31 | 산텐 세이야꾸 가부시키가이샤 | 안정한 제제와 그 제조 및 사용 방법 |
| AU2007230964B2 (en) | 2006-03-23 | 2012-07-19 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
| US20090291883A1 (en) * | 2006-07-14 | 2009-11-26 | Boston Medical Center Corporation | Combination of an immunosuppressive agent and nonsteroidal anti -inflammatory drugs to treat disease |
| US20090017140A1 (en) * | 2007-07-09 | 2009-01-15 | Peter Koepke | Maytenus abenfolia extract and methods of extracting and using such extract |
| US20090035395A1 (en) * | 2007-08-01 | 2009-02-05 | Peter Koepke | Spondias mombin l. extract and methods of extracting and using such extract |
| US7879369B2 (en) * | 2007-09-18 | 2011-02-01 | Selvamedica, Llc | Combretum laurifolium Mart. extract and methods of extracting and using such extract |
| US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59196839A (ja) | 1983-04-21 | 1984-11-08 | Sankyo Co Ltd | フエニル酢酸誘導体 |
| US4923891A (en) | 1987-09-24 | 1990-05-08 | G. D. Searle & Co. | Leukotriene LTD4 and LTB4 antagonists |
| US4970234A (en) | 1987-12-08 | 1990-11-13 | G. D. Searle & Co. | Furyl, phenylene, and thienyl leukotriene B4 analogues |
| US4889935A (en) | 1987-12-18 | 1989-12-26 | American Home Products Corporation | Aminoguanidine derivatives |
| US4871771A (en) | 1988-02-04 | 1989-10-03 | Smithkline Beckman Corporation | Leukotriene antagonists |
| US5384318A (en) * | 1989-06-22 | 1995-01-24 | Pfizer Inc. | Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases |
| US5256686A (en) | 1989-06-27 | 1993-10-26 | Ono Pharmaceutical Co., Ltd. | Phenylalkan(en)oic acid |
| US5212198A (en) | 1990-05-10 | 1993-05-18 | G. D. Searle & Co. | Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof |
| US5121198A (en) * | 1990-06-28 | 1992-06-09 | Eastman Kodak Company | Method of setting the contrast of a color video picture in a computer controlled photographic film analyzing system |
| US5124350A (en) | 1990-06-28 | 1992-06-23 | G. D. Searle & Co. | Leukotriene b4 antagonists |
| FR2665159B1 (fr) | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| JPH0439864U (enExample) * | 1990-07-30 | 1992-04-03 | ||
| US5232948A (en) | 1990-09-10 | 1993-08-03 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted monocyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity |
| US5210208A (en) | 1990-09-24 | 1993-05-11 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity |
| IE913655A1 (en) | 1990-11-06 | 1992-05-22 | Zeneca Ltd | Synergistic agents |
| US5246965A (en) * | 1991-06-11 | 1993-09-21 | Ciba-Geigy | Arylethers, their manufacture and methods of treatment |
| US5272178A (en) | 1991-11-18 | 1993-12-21 | G. D. Searle & Co. | Compounds of cyclic phenolic thioethers which are useful in stimulating and inhibiting superoxide generation |
| DE4141746A1 (de) * | 1991-12-13 | 1993-06-17 | Schering Ag | 20-methyl-substituierte vitamin d-derivate |
| GB9215921D0 (en) | 1992-07-27 | 1992-09-09 | Wellcome Found | Anti-inflammatory compounds |
| DE4228201A1 (de) * | 1992-08-25 | 1994-03-03 | Schering Ag | Neue Leukotrien-B¶4¶-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
| AU6027694A (en) | 1993-01-15 | 1994-08-15 | G.D. Searle & Co. | Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents |
| US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
| US5380740A (en) | 1993-04-28 | 1995-01-10 | G. D. Searle & Co. | Anti-inflammatory compounds, compositions and method of use thereof |
| CA2161789A1 (en) | 1993-05-13 | 1994-11-24 | Jacques Yves Gauthier | 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase |
| US5380738A (en) | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5412151A (en) | 1993-10-22 | 1995-05-02 | Eastman Chemical Company | Thermosetting coating compositions |
| US5344991A (en) | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
| US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| CA2277954A1 (en) * | 1993-11-30 | 1995-06-08 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
| US5434178A (en) | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
| WO1995015932A1 (en) | 1993-12-09 | 1995-06-15 | Harima Ceramic Co., Ltd. | Chromium-free brick |
| US5393790A (en) | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
| US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| US5620999A (en) * | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
| US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
| US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
| US5686470A (en) * | 1995-02-10 | 1997-11-11 | Weier; Richard M. | 2, 3-substituted pyridines for the treatment of inflammation |
| US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| US5700816A (en) * | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| US6342510B1 (en) * | 1995-06-12 | 2002-01-29 | G. D. Searle & Co. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist |
| US6096728A (en) * | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| ES2243978T3 (es) * | 1996-02-13 | 2005-12-01 | G.D. SEARLE & CO. | Composiciones que comprenden un inhibidor de la ciclooxigenasa-2 y un antagonista del receptor de leucotrieno b4. |
-
1997
- 1997-02-11 ES ES97905663T patent/ES2243978T3/es not_active Expired - Lifetime
- 1997-02-11 PT PT97905663T patent/PT880362E/pt unknown
- 1997-02-11 EP EP05003990A patent/EP1640003A2/en not_active Withdrawn
- 1997-02-11 EP EP97905663A patent/EP0880362B1/en not_active Expired - Lifetime
- 1997-02-11 WO PCT/US1997/001422 patent/WO1997029775A1/en not_active Ceased
- 1997-02-11 AT AT97905663T patent/ATE296114T1/de not_active IP Right Cessation
- 1997-02-11 DE DE69733338T patent/DE69733338T2/de not_active Expired - Fee Related
- 1997-02-11 JP JP9529359A patent/JP2000505445A/ja not_active Ceased
- 1997-02-11 CA CA002246356A patent/CA2246356A1/en not_active Abandoned
- 1997-02-11 AU AU22500/97A patent/AU2250097A/en not_active Abandoned
-
1998
- 1998-05-11 US US09/075,633 patent/US6172096B1/en not_active Expired - Fee Related
-
2000
- 2000-09-12 US US09/659,299 patent/US6617345B1/en not_active Expired - Fee Related
-
2003
- 2003-07-10 US US10/617,222 patent/US7141599B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20040106668A1 (en) | 2004-06-03 |
| ES2243978T3 (es) | 2005-12-01 |
| PT880362E (pt) | 2005-10-31 |
| JP2000505445A (ja) | 2000-05-09 |
| US6172096B1 (en) | 2001-01-09 |
| ATE296114T1 (de) | 2005-06-15 |
| US6617345B1 (en) | 2003-09-09 |
| DE69733338D1 (de) | 2005-06-30 |
| DE69733338T2 (de) | 2006-03-16 |
| CA2246356A1 (en) | 1997-08-21 |
| EP0880362B1 (en) | 2005-05-25 |
| EP0880362A1 (en) | 1998-12-02 |
| WO1997029775A1 (en) | 1997-08-21 |
| US7141599B2 (en) | 2006-11-28 |
| EP1640003A2 (en) | 2006-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE296114T1 (de) | Zubereitungen, enthaltend einen cyclooxygenase-2- inhibitor und einen leukotrien-b4-rezeptor- antagonisten | |
| CA2249009A1 (en) | Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors | |
| NZ509755A (en) | Method of using benzenesulphoamides that are cyclooxygenase-2-inhibitors in the treatment and prevention of neoplasia | |
| JP2004526765A5 (enExample) | ||
| US20040131670A1 (en) | Pellicle-resistant gelatin capsule | |
| ZA200307630B (en) | Reconstitutable parenteral composition containing a cox-2-inhibitor. | |
| RU99110192A (ru) | Способ применения ингибиторов циклооксигеназы-2 для лечения и профилактики неоплазии | |
| KR100765614B1 (ko) | 유방염 및 이질환 치료용 분산성 제약 조성물 | |
| RU2325189C2 (ru) | Способ и фармацевтическая композиция для доставки противовоспалительного средства | |
| CA2533101A1 (en) | Dispersible formulation of an anti-inflammatory agent | |
| CA2286673A1 (en) | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders | |
| US20040204469A1 (en) | Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders | |
| Bánóczy et al. | Milk fluoridation for the prevention of dental caries | |
| US20040105885A1 (en) | Gelatin capsule exhibiting reduced cross-linking | |
| WO2004010974A2 (en) | Gelatin capsule exhibiting reduced cross-linking | |
| JP2005501083A5 (enExample) | ||
| AR020306A1 (es) | Composicion terapeutica y su uso como inhibidora de la ciclooxigenasa-2 en la prevencion de alteraciones cardiovasculares. | |
| JP2001521889A5 (enExample) | ||
| Shimizu et al. | Clinical and histological analysis of acute tacrolimus (TAC) nephrotoxicity in renal allografts | |
| Sutherland et al. | Liposomal amphotericin B associated with severe hyperphosphatemia | |
| ZA200307575B (en) | Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2inhibitor), a solvent, a fatty acid and an organic amine. | |
| AR014000A1 (es) | Metodo para utilizar inhibidores de ciclooxigenasa-2 en el mantenimiento del ductus ateriosus fetal durante el tratamiento y la prevencion del trabajode parto prematuro | |
| ANECDOTES | administratiou, marriages were | |
| National Toxicology Program | Carcinogenesis Bioassay of Vinylidene Chloride (CAS No. 75-35-4) in F344 Rats and B6C3F1 Mice (Gavage Study) | |
| Yule | GEOGRAPHY AND MASSACRE. |